5 azacitidine

Manufactured by Selleck Chemicals

Sourced in United States

5-azacitidine is a chemical compound that functions as a nucleoside analog. It is commonly used as a laboratory reagent in various research applications.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

5-Azacitidine (5-Aza) Azacitidine

2 protocols using 5 azacitidine

Overexpression of GRHL2 and Epigenetic Modulations

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lenti-X Tet-On 3G-Inducible Expression System (Clontech) was used for GRHL2 overexpression. The complementary DNA (cDNA) of GRHL2 was cloned into pLVX-TRE3G vector (631191, Clontech) using standard molecular cloning techniques. The mutated GRHL2* (resistant to shGRHL2 #12) was generated by introducing four silent point mutations to the wild-type cDNA using QuickChangeII XL Site-Directed Mutagenesis Kit (Agilent). The 293T cells were transfected with pLVX-Tet3G, viral packaging mix, and pLVX-TRE3G-GRHL2 or pLVX-TRE3G-GRHL2* using Lenti-X HTX Packaging Mix 2 System (631260, Clontech). Viruses were harvested to infect IOSE523, HeyA8, and OVCA429 shGRHL2 #12 cells. GRHL2 expression was induced by doxycycline (1 μg/ml for 48 or 96 h). Cells were treated with GSK126 (S7061, Selleck Chemicals) at a final concentration of 5 μM for 72 h; mocetinostat (S1122, Selleck Chemicals) at 1 μM (OVCA429 shGRHL2 Tet-GRHL2*) or 0.5 μM (IOSE523 and HeyA8) for 48 h; 5-azacitidine (S1782, Selleck Chemicals) at 1 μM for 144 h.

Chung V.Y., Tan T.Z., Ye J., Huang R.L., Lai H.C., Kappei D., Wollmann H., Guccione E, & Huang R.Y. (2019). The role of GRHL2 and epigenetic remodeling in epithelial–mesenchymal plasticity in ovarian cancer cells. Communications Biology, 2, 272.

+ Open protocol

+ Expand

Dose-dependent drug response assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Response to single drugs or drug combinations was assessed after 72 h of exposure to increasing doses of the drug followed by an MTT assay. Copanlisib, duvelisib, umbralisib, everolimus, bimiralisib, vincristine, 5-azacitidine, masitinib, stattic and tocilizumab were purchased from Selleckchem, Lin28-1632 (LIN1632) from R&D Systems (Minneapolis, MN, USA), and human recombinant interleukin 6 (IL-6; CYT-213) from Prospec (Rehovot, Israel). Loncastuximab tesirine was kindly provided by ADC Therapeutics (Epalinges, Switzerland). Details are provided in the Online Supplementary Methods.

Arribas A.J., Napoli S., Cascione L., Sartori G., Barnabei L., Gaudio E., Tarantelli C., Mensah A.A., Spriano F., Zucchetto A., Rossi F.M., Rinaldi A., de Moura M.C., Jovic S., Bordone-Pittau R., Di Veroli A., Stathis A., Cruciani G., Stussi G., Gattei V., Brown J.R., Esteller M., Zucca E., Rossi D, & Bertoni F. (2022). Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Haematologica, 107(11), 2685-2697.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!